Chiang, Anne C.
Herbst, Roy S.
Article History
First Online: 6 January 2020
Competing interests
: R.S.H. has received honoraria for consultancy from Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly, EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Midas Health Analytics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, and Tocagen. R.S.H. has also received research support from AstraZeneca, Eli Lilly and Merck, and is a member of the board of directors (non-executive/ independent) for Junshi Pharmaceuticals. A.C.C. has received honoraria for consultancy or participation on advisory boards from Abbvie Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb and Genentech/Roche. A.C.C. has also received research support from AbbVIe Pharmaceuticals, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Merck.